|
Title
|
|
|
|
LifePearl microspheres loaded with irinotecan in the treatment of Liver-dominant metastatic colorectal carcinoma : feasibility, safety and pharmacokinetic study
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| To evaluate pharmacokinetic and safety profile of LifePearl microspheres loaded with irinotecan (LifePearl-IRI) in the treatment of liver-dominant, metastatic colorectal carcinoma (LM-CRC) by transarterial chemoembolization. In a prospective, multicentre pharmacokinetic study, 14 patients with LM-CRC progressing on at least one line of chemotherapy were treated with LifePearl-IRI. Six patients received unilobar treatment, treating one lobe per session with 100 mg of irinotecan every 2 weeks. Eight patients received bilobar treatment, treating two lobes per session with 100 mg of irinotecan each (200 mg in total), every 4 weeks. At 24 h, near complete plasma clearance occurred for both irinotecan and SN-38, regardless of the dose. Mean plasma C(max(100 mg))was 254.50 +/- 104.17 ng/mL for irinotecan and 46.72 +/- 13.75 ng/mL for SN-38. Mean C(max(200 mg))was 970.09 +/- 353.75 ng/mL for irinotecan and 118.45 +/- 25.11 ng/mL for SN-38. Significantly higher Cmax-iri((200 mg))than Cmax-iri((100 mg))supported rate-limiting irinotecan-to-SN-38 conversion. Adverse events during the first 30 days upon initial treatment were hypertension in 21.4%, abdominal pain in 14.3%, and increased transaminases and fever in 7.1% of patients. Four serious adverse events were noted: respiratory failure, constipation, necrotizing pancreatitis, and ischaemic cholecystitis. Chemoembolization with LifePearl-IRI is technically feasible and relatively well tolerated, with a good pharmacokinetic profile and minimal systemic exposure of both irinotecan and SN-38, after both unilobar and bilobar treatment with 100 or 200 mg, respectively. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Anti-cancer drugs: an international journal on anti-cancer agents. - Philadelphia, Pa
| |
|
Publication
|
|
|
|
Philadelphia, Pa
:
2020
| |
|
ISSN
|
|
|
|
0959-4973
| |
|
DOI
|
|
|
|
10.1097/CAD.0000000000000980
| |
|
Volume/pages
|
|
|
|
31
:10
(2020)
, p. 1084-1090
| |
|
ISI
|
|
|
|
000580389200012
| |
|
Pubmed ID
|
|
|
|
32932279
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|